Background: Elevated interleukin (IL)-6 levels have been linked to adverse outcomes in patients with and without baseline cardiovascular disease (CVD)., Objectives: The purpose of this study was to examine the association between circulating IL-6 levels and CVD events without baseline CVD across racial and ethnic groups., Methods: We conducted an observational analysis utilizing the MESA (Multi-Ethnic Study of Atherosclerosis), a multicenter, prospective community-based study of CVD at baseline from four racial and ethnic groups. IL-6 levels were measured at the time of enrollment (visit 1) and were divided into 3 terciles. Patient baseline characteristics and outcomes, including all-cause mortality, CV mortality, heart failure, and non-CV mortality, were included. Cox proportional hazard regression models were used to assess associations between IL-6 levels and study outcomes with IL-6 tercile 1 as reference., Results: Of 6,622 individuals, over half were women (53%) with a median age of 62 (IQR: 53-70) years. Racial and ethnic composition was non-Hispanic White (39%) followed by African American (27%), Hispanic (22%), and Chinese American (12%). Compared to tercile 1, participants with IL-6 tercile 3 had a higher adjusted risk of and all-cause mortality (HR: 1.98 [95% CI: 1.67-2.36]), CV mortality (HR: 1.55 [95% CI: 1.05-2.30]), non-CV mortality (HR: 2.05 [95% CI: 1.65-2.56]), and heart failure (HR: 1.48 [95% CI: 0.99-2.19]). When tested as a continuous variable, higher levels of IL-6 were associated with an increased risk of all individual outcomes. Compared to non-Hispanic White participants, the unadjusted and adjusted risk of all outcomes across all races and ethnicities was similar across all IL-6 terciles., Conclusions: High levels of circulating IL-6 are associated with worse CV outcomes and increased all-cause mortality consistently across all racial and ethnic groups., Competing Interests: Dr Rymer has received research grant support from 10.13039/100007560Chiesi Pharmaceuticals, 10.13039/501100016198Idorsia Pharmaceuticals, and the 10.13039/100000968American Heart Association; and personal fees from Chiesi Pharmaceuticals outside the submitted work. Dr Borlaug has received research support from the 10.13039/100000002National Institutes of Health (R01 HL128526, R01 HL162828, and U01 HL160226) and the 10.13039/100000005United States Department of Defense (W81XWH2210245); has received research grant funding from 10.13039/100004325AstraZeneca, Axon, 10.13039/100004330GlaxoSmithKline, 10.13039/100004374Medtronic, Mesoblast, 10.13039/100015758Novo Nordisk, and 10.13039/100016949Tenax Therapeutics; has served as a consultant for Actelion, Amgen, Aria, BD, Boehringer Ingelheim, Cytokinetics, Edwards Lifesciences, Eli Lilly, Janssen, Merck, and Novo Nordisk; and is a named inventor (US Patent no. 10307179) for the tools and approach for a minimally invasive pericardial modification procedure to treat heart failure. Dr Cikes has received research grants and clinical study contracts to institution from 10.13039/100004336Novartis, 10.13039/100000046Abbott, 10.13039/100004319Pfizer, and CorVia; and personal fees and nonfinancial support from 10.13039/100004319Pfizer, 10.13039/100004326Bayer, 10.13039/100001003Boehringer Ingelheim, 10.13039/100004325AstraZeneca, 10.13039/100004336Novartis, Swixx, 10.13039/100020297Abiomed, 10.13039/100015362Amicus, 10.13039/100002429Amgen, 10.13039/100015758Novo Nordisk, 10.13039/100004374Medtronic, 10.13039/100006775GE Healthcare, 10.13039/100006259Teva Pharmaceutical Industries, and Krka Pharma. Dr Docherty reports that his employer, the University of Glasgow, has been remunerated by AstraZeneca for work relating to clinical trials; he has received speaker honoraria from AstraZeneca, Pharmacosmos, and Radcliffe Cardiology; has served on an advisory board for Us2.ai and Bayer AG; has served on a clinical end point committee for Bayer AG; and has received grant support from 10.13039/100001003Boehringer Ingelheim, 10.13039/100016545Roche Diagnostics, and 10.13039/100004325AstraZeneca (paid to his institution). Dr Pandey is supported by the Texas Health Resources Clinical Scholarship, the 10.13039/100005564Gilead Sciences Research Scholars Program, the 10.13039/100000049National Institute on Aging GEMSSTAR Grant (1R03AG067960-01) and Applied Therapeutics; has served on the advisory board for Roche Diagnostics; and has received nonfinancial support from 10.13039/100004319Pfizer and 10.13039/100004334Merck. Dr Kahles has served as a consultant to Bayer and Novo Nordisk and has served as a speaker for Novo Nordisk. Dr Lam is supported by a Clinician Scientist Award from the 10.13039/501100001349National Medical Research Council of Singapore; has received research support from 10.13039/100004326Bayer and 10.13039/100016545Roche Diagnostics; has served as consultant or on the Advisory Board, Steering Committee, or Executive Committee for Actelion, Alleviant Medical, Allysta Pharma, Amgen, AnaCardio AB, Applied Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Cytokinetics, Darma Inc, EchoNous Inc, Eli Lilly, Impulse Dynamics, Ionis Pharmaceutical, Janssen Research & Development LLC, Medscape/WebMD Global LLC, Merck, Novartis, Novo Nordisk, Prosciento Inc, Radcliffe Group Ltd, Roche Diagnostics, Sanofi, Siemens Healthcare Diagnostics and Us2.ai; and has served as cofounder and non–executive director of Us2.ai. The employer of AAV has received consultancy fees and research support from AnaCardio, 10.13039/100004325AstraZeneca, 10.13039/100002491BMS, 10.13039/100004326Bayer, 10.13039/100001003Boehringer Ingelheim, Corteria, EliLilly, 10.13039/100004334Merck, 10.13039/100019533Moderna, 10.13039/100004336Novartis, 10.13039/100015758Novo Nordisk, 10.13039/100016545Roche Diagnostics. Dr Hernandez has received grants from Intellia Therapeutics; compensation from Prolaio for consultant services; grants from 10.13039/100004326Bayer; compensation from Eli Lilly and Company for consultant services; compensation from Novo Nordisk for consultant services; employment by Duke Clinical Research Institute; compensation from Intercept Pharmaceuticals, Inc, for data and safety monitoring services; grants from 10.13039/100001003Boehringer Ingelheim; compensation from CSL Behring for consultant services; compensation from Boehringer Ingelheim for consultant services; compensation from Amgen for consultant services; compensation from Novartis for consultant services; grants from 10.13039/100018044Verily; compensation from Merck for consultant services; grants from 10.13039/100016473American Regent; compensation from AstraZeneca for consultant services; compensation from Eidos for data and safety monitoring services; compensation from Cytokinetics for consultant services; grants from 10.13039/100015758Novo Nordisk Inc, 10.13039/100004336Novartis, AstraZeneca, and 10.13039/100001238Merck; compensation from Bayer for consultant services; and compensation from Boston Scientific Corporation and Intellia Therapeutics for consultant services. Dr Lincoff has received Esperion research funding for this trial; grants from Eli Lilly, 10.13039/100006483AbbVie, 10.13039/100008322CSL, 10.13039/100004325AstraZeneca, and 10.13039/100004336Novartis; and personal fees from Novo Nordisk, Glaxo, Akebia, Endologix, Fibrogen, Provention, and Becton Dickson. Dr Petrie has received grants from 10.13039/100001003Boehringer Ingelheim, 10.13039/100004337Roche, SQ Innovations, Astra Zeneca, 10.13039/100004336Novartis, 10.13039/100015758Novo Nordisk, 10.13039/100004374Medtronic, 10.13039/100008497Boston Scientific, Horizon, Pharmacosmos; consulting fees from Boehringer Ingelheim, Novartis, AstraZeneca, Novo Nordisk, Abbvie, Bayer, Takeda, Corvia, Cardiorentis, Pharmacosmos, Siemens, and Vifor; lecture fees from Boehringer Ingelheim, Novartis, Astra Zeneca, Novo Nordisk, Abbvie, Bayer, Takeda, Corvia, Cardiorentis, Pharmacosmos, Siemens, and Vifor; board participation for Teikoku and Astra Zeneca; and is the Director of Global Clinical Trial Partners Ltd. Dr Ridker has received institutional research grant support from the 10.13039/100000050NHLBI, 10.13039/100004336Novartis, and 10.13039/100015758Novo Nordisk (to evaluate the role of anti-inflammatory agents including methotrexate, interleukin-1 inhibitors, and interleukin-6 inhibitors) as well as Kowa, Amarin, Pfizer, and Esperion; has served as a consultant to Novartis, Novo Nordisk, Janssen, Flame, Agepha, Ardelyx, Zomagen, Horizon Therapeutics, CSL Behring, and Cardio Therapeutics (entities developing anti-inflammatory therapies including as examples colchicine, interleukin-1 inhibitors, interleukin-6 inhibitors, and agents that potentially target or interact with the NLRP3 inflammasome); has additionally served as a consultant to AstraZeneca, Civi Biopharm, Glaxo Smith Kline, SOCAR, Health Outlook, Montai Health, Eli Lilly, New Amsterdam, Boehringer-Ingelheim, RTI, and Cytokinetics; has minority shareholder equity positions in Uppton, Bitteroot Bio, and Angiowave; and has received compensation for service on the Peter Munk Advisory Board (University of Toronto), the Leducq Foundation, Paris FR, and the Baim Institute (Boston, MA). Dr Fudim was supported by the 10.13039/100000968American Heart Association (20IPA35310955), Doris Duke, 10.13039/100004326Bayer, Bodyport and Verily; has received consulting fees from Abbott, Ajax, Alio Health, Alleviant, Audicor, Axon Therapies, Bayer, BodyGuide, Bodyport, Boston Scientific, Broadview, Cadence, Cardionomics, Coridea, CVRx, Daxor, Deerfield Catalyst, Edwards Lifesciences, EKO, Feldschuh Foundation, FIRE1, Gradient, Hatteras, Impulse Dynamics, InterShunt, Medtronic, NI Medical, NXT Biomedical, Pharmacosmos, PreHealth, ReCor, Shifamed, Splendo, Summacor, SyMap, Verily, Vironix, VisCardia and Zoll outside the submitted work. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose., (© 2024 The Authors.)